Cephalgiadrugs Banned News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New Drug for Migraine Approved
by Colleen Fleiss on 
February 25, 2021 at 8:03 AM
The US Food & Drug Administration (US FDA) has approved Granules Abbreviated New Drug Application (ANDA) for acetaminophen, aspirin, and caffeine tablets, indicated for the treatment of migraine.
It is bioequivalent to the Reference Listed Drug (RLD) product, Excedrin Migraine tablets, 250 mg/250 mg/65 mg, of GlaxoSmithKline Consumer Healthcare.
The product would be manufactured at Granules India s Hyderabad facility and is expected to be launched shortly.
‘Granules’ Abbreviated New Drug Application (ANDA) for acetaminophen, aspirin, and caffeine tablets, indicated for migraine treatment has been approved by USFDA. ’
We are pleased to announce approval of Acetaminophen, Aspirin and Caffeine tablets, emphasising our focus on building a sustainable OTC product portfolio in the US market. We received approval for this triple combination product ....

Andhra Pradesh , Priyanka Chigurupati , Migrainemenstrual Migrainedrug , Granules Pharmaceuticals Inc , Us Food Drug Administration , Drug Administration , Granule Abbreviated New Drug Application , Reference Listed Drug , Excedrin Migraine , Glaxosmithkline Consumer , Granules India , Executive Director , Granules Pharmaceuticals , Toxicitymigraineclinical Trials , Signature Drug Toxicityheadache , Cephalgiadrugs Banned , Indiaheadache Symptom Evaluationretinal Migraine , Ocular Migrainemenstrual Migrainedrug Induced , Migraine Drugs , Migraine Treatment , ஆந்திரா பிரதேஷ் , பிரியாங்க சிகுருபடி , துகள்கள் மருந்துகள் இன்க் , குறிப்பு பட்டியலிடப்பட்டுள்ளது மருந்து , கிளாக்சோஸ்மித்க்லைன் நுகர்வோர் , துகள்கள் இந்தியா ,